Full identifier: http://purl.org/np/RADRUiOUh6uuN0__OVfjoOYe6_XJv7jSXxXq9IIuy9-os#assertion
| Nanopublication | Part | Subject | Predicate | Object | Published By | Published On |
|---|---|---|---|---|---|---|
|
links a nanopublication to its provenance
http://www.nanopub.org/nschema#hasProvenance
provenance
|
assertion
|
Elif Ozkan
|
2022-10-13T13:08:12.626Z
|
|||
|
links a nanopublication to its provenance
http://www.nanopub.org/nschema#hasProvenance
provenance
|
assertion
|
2022-10-13T13:08:12.626083
|
Elif Ozkan
|
2022-10-13T13:08:12.626Z
|
||
|
links a nanopublication to its provenance
http://www.nanopub.org/nschema#hasProvenance
provenance
|
assertion
|
fosinopril is indicated For treating mild to moderate hypertension, use as an adjunct in treating congestive heart failure, and may be used to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy. Use as adjunct to treating heart failure and may also be used in those with heart failure. Use of an adjunct to slow progression of kidney disease in those suffering from hypertension.
|
Elif Ozkan
|
2022-10-13T13:08:12.626Z
|